Aldeyra Therapeutics (NASDAQ:ALDX) Stock: Insider Richard Douglas Acquires 200,000 Shares

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Director Richard Douglas purchased 200,000 shares of the stock in a transaction on Wednesday, November 11th. The stock was acquired at an average price of $0.64 per share, with a total value of $128,000.00. Following the completion of the acquisition, the director directly owned 395,000 shares of the company’s stock, valued at approximately $252,800. This represents a 102.56% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Aldeyra Therapeutics Trading Up 2.2%

Shares of NASDAQ ALDX traded up $0.01 during mid-day trading on Friday, reaching $0.64. 734,135 shares of the company’s stock were exchanged, compared to its average volume of 867,410. The firm has a market capitalization of $38.86 million, a price-to-earnings ratio of -2.01 and a beta of 1.32. The business has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $2.09. Aldeyra Therapeutics, Inc. has a twelve month low of $0.53 and a twelve month high of $5.93.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.05. Equities research analysts predict that Aldeyra Therapeutics, Inc. will post -0.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALDX shares. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, September 14th. BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, September 29th. Finally, HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of Aldeyra Therapeutics in a report on Wednesday, September 30th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $2.00.

Institutional Trading of Aldeyra Therapeutics

A number of institutional investors have recently modified their holdings of ALDX. Squarepoint Ops LLC acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $200,000. Two Sigma Securities LLC bought a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $70,000. Palo Alto Investors LP acquired a new position in Aldeyra Therapeutics during the 2nd quarter worth approximately $331,660. Bank of America Corp DE acquired a new position in Aldeyra Therapeutics during the 2nd quarter worth approximately $72,000. Finally, Man Group plc acquired a new position in Aldeyra Therapeutics during the 2nd quarter worth approximately $325,000. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.